{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:54:18Z","timestamp":1768622058481,"version":"3.49.0"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-14-00006"],"award-info":[{"award-number":["19-14-00006"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Following the WHO announcement of smallpox eradication, discontinuation of smallpox vaccination with vaccinia virus (VACV) was recommended. However, interest in VACV was soon renewed due to the opportunity of genetic engineering of the viral genome by directed insertion of foreign genes or introduction of mutations or deletions into selected viral genes. This genomic technology enabled production of stable attenuated VACV strains producing antigens of various infectious agents. Due to an increasing threat of human orthopoxvirus re-emergence, the development of safe highly immunogenic live orthopoxvirus vaccines using genetic engineering methods has been the challenge in recent years. In this study, we investigated an attenuated VACV LIVP-GFP (TK-) strain having an insertion of the green fluorescent protein gene into the viral thymidine kinase gene, which was generated on the basis of the LIVP (Lister-Institute for Viral Preparations) strain used in Russia as the first generation smallpox vaccine. We studied the effect of A34R gene modification and A35R gene deletion on the immunogenic and protective properties of the LIVP-GFP strain. The obtained data demonstrate that intradermal inoculation of the studied viruses induces higher production of VACV-specific antibodies compared to their levels after intranasal administration. Introduction of two point mutations into the A34R gene, which increase the yield of extracellular enveloped virions, and deletion of the A35R gene, the protein product of which inhibits presentation of antigens by MHC II, enhances protective potency of the created LIVP-TK--A34R*-dA35R virus against secondary lethal orthopoxvirus infection of BALB\/c mice even at an intradermal dose as low as 103 plaque forming units (PFU)\/mouse. This virus may be considered not only as a candidate attenuated live vaccine against smallpox and other human orthopoxvirus infections but also as a vector platform for development of safe multivalent live vaccines against other infectious diseases using genetic engineering methods.<\/jats:p>","DOI":"10.3390\/pathogens10030377","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T23:47:41Z","timestamp":1616370461000},"page":"377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice"],"prefix":"10.3390","volume":"10","author":[{"given":"Sergei N.","family":"Shchelkunov","sequence":"first","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav N.","family":"Yakubitskiy","sequence":"additional","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kseniya A.","family":"Titova","sequence":"additional","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stepan A.","family":"Pyankov","sequence":"additional","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Sergeev","sequence":"additional","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.32607\/actanaturae.10935","article-title":"Genes that control vaccinia virus immunogenicity","volume":"12","author":"Shchelkunov","year":"2020","journal-title":"Acta Nat."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Shchelkunov, S.N. (2013). An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003756"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"Perdiguero","year":"2015","journal-title":"Viruses"},{"key":"ref_4","unstructured":"Shchelkunov, S.N., Marennikova, S.S., and Moyer, R.W. (2005). Orthopoxviruses Pathogenic for Humans, Springer."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kretzschmar, M., Wallinga, J., Teunis, P., Xing, S., and Mikolajczyk, R. (2006). Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030429"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: Past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res."},{"key":"ref_7","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Eradication, World Health Organization."},{"key":"ref_8","unstructured":"World Health Assembly (1980). Global Smallpox Eradication, World Health Organization."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Olson, V.A., and Shchelkunov, S.N. (2017). Are we prepared in case of a possible smallpox-like disease emergence?. Viruses, 9.","DOI":"10.3390\/v9090242"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Albarnaz, J.D., Torres, A.A., and Smith, G.L. (2018). Modulating vaccinia virus immunomodulators to improve immunological memory. Viruses, 10.","DOI":"10.3390\/v10030101"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14787210.2019.1567330","article-title":"Monkeypox re-emergence in Africa: A call to expand the concept and practice of One Health","volume":"17","author":"Reynolds","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3201\/eid2512.181114","article-title":"Seroprevalence and risk factors possibly associated with emerging zoonotic vaccinia virus in a farming community, Colombia","volume":"25","author":"Styczynski","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: Targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2011.05.037","article-title":"Emergence and reemergence of smallpox: The need in development of a new generation smallpox vaccine","volume":"29S","author":"Shchelkunov","year":"2011","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1023\/A:1024476626759","article-title":"Development of a candidate polyvalent live vaccine against human immunodeficiency, hepatitis B, and orthopoxviruses","volume":"390","author":"Shchelkunov","year":"2003","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1134\/S1607672918010088","article-title":"Virotherapy of the malignant U87 human glioblastoma in the orthotopic xenotransplantation mouse SCID model","volume":"478","author":"Shchelkunov","year":"2018","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mt.2010.312","article-title":"Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer","volume":"19","author":"Li","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1186\/s12967-016-1002-x","article-title":"Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro","volume":"14","author":"Goncharova","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fcimb.2017.00462","article-title":"Generation of an attenuated Tiantan vaccinia virus strain by deletion of multiple genes","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2567.2009.03120.x","article-title":"Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II","volume":"128","author":"Rehm","year":"2009","journal-title":"Immunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.virol.2009.11.008","article-title":"Vaccinia virus A35R inhibits MHC class II antigen presentation","volume":"397","author":"Rehm","year":"2010","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1016\/j.vaccine.2011.02.023","article-title":"Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching","volume":"29","author":"Rehm","year":"2011","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1134\/S1607672916010105","article-title":"Highly immunogenic variant of attenuated vaccinia virus","volume":"466","author":"Yakubitskiy","year":"2016","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J. Gen. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/jvi.67.6.3319-3325.1993","article-title":"Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: Effect of a point mutation in the lectin homology domain of the A34R gene","volume":"67","author":"Blasco","year":"1993","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1091\/mbc.11.7.2497","article-title":"Entry of the two infectious forms of vaccinia virus at the plasma membrane is signaling-dependent for IMV but not the EEV","volume":"11","author":"Locker","year":"2000","journal-title":"Mol. Biol. Cell."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1128\/JVI.02391-10","article-title":"The host phosphoinositide 5-phosphatase SHIP2 regulates dissemination of vaccinia virus","volume":"85","author":"McNulty","year":"2011","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01343-18","DOI":"10.1128\/JVI.01343-18","article-title":"The ectodomain of the vaccinia virus glycoprotein A34 is required for cell binding by extracellular virions and contains a large region capable of interaction with glycoprotein B5","volume":"93","author":"Monticelli","year":"2019","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/jvi.66.5.2617-2630.1992","article-title":"Molecular attenuation of vaccinia virus: Mutant generation and animal characterization","volume":"66","author":"Lee","year":"1992","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-07-6515","article-title":"Enhancing poxvirus oncolytic effects through increased spread and immune evasion","volume":"68","author":"Kirn","year":"2008","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/mt.2013.27","article-title":"A rationally designed A34R mutant oncolytic poxvirus: Improved efficacy in peritoneal carcinomatosis","volume":"21","author":"Thirunavukarasu","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.32607\/20758251-2015-7-4-113-121","article-title":"Attenuation of vaccinia virus","volume":"7","author":"Yakubitskiy","year":"2015","journal-title":"Acta Nat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1134\/S0012496613040133","article-title":"Antitumor effect of the LIVP-GFP recombinant vaccinia virus","volume":"45","author":"Petrov","year":"2013","journal-title":"Dokl. Biol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15789\/1563-0625-OVV-1594","article-title":"Obtaining vaccinia virus with increased production of extracellular enveloped virions and directing GM-CSF synthesis as a promising basis for development of antitumor drug","volume":"22","author":"Bauer","year":"2020","journal-title":"Med. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1006\/viro.1998.9039","article-title":"The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins","volume":"243","author":"Shchelkunov","year":"1998","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.1470917","article-title":"Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene","volume":"258","author":"Daniel","year":"1992","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1128\/iai.65.9.3539-3546.1997","article-title":"A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence","volume":"65","author":"Sanglard","year":"1997","journal-title":"Infect. Immun. Actions"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.micinf.2005.04.001","article-title":"Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis","volume":"7","author":"Sambandamurthy","year":"2005","journal-title":"Microbes Infect. Actions"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26824","DOI":"10.1038\/srep26824","article-title":"Protective efficacy and safety of liver stage attenuated malaria parasites","volume":"6","author":"Kumar","year":"2016","journal-title":"Sci. Rep. Actions"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1099\/vir.0.049486-0","article-title":"Transport and stability of the vaccinia virus A34 protein is affected by the A33 protein","volume":"94","author":"Breiman","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1128\/JVI.01971-07","article-title":"The vaccinia virus B5 protein requires A34 for efficient intracellular trafficking from the endoplasmic reticulum to the site of wrapping and incorporation into progeny virions","volume":"82","author":"Earley","year":"2008","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/jvi.70.1.272-281.1996","article-title":"Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus","volume":"70","author":"McIntosh","year":"1996","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.32607\/actanaturae.10972","article-title":"The influence of an elevated production of extracellular enveloped virions of the vaccinia virus on its properties in infected mice","volume":"12","author":"Shchelkunov","year":"2020","journal-title":"Acta Nat."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Strnadova, P., Ren, H., Valentine, R., Mazzon, M., Sweeney, T.R., Brierley, I., and Smith, G.L. (2015). Inhibition of translation initiation by protein 169: A vaccinia virus strategy to suppress innate and adaptive immunity and alter virus virulence. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005151"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.vaccine.2003.10.022","article-title":"Mouse neurotoxicity test for vaccinia-based smallpox vaccines","volume":"22","author":"Li","year":"2004","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shchelkunov, S.N., Yakubitskiy, S.N., Sergeev, A.A., Kabanov, A.S., Bauer, T.V., Bulichev, L.E., and Pyankov, S.A. (2020). Effect of the route of administration of the vaccinia virus strain LIVP to mice on its virulence and immunogenicity. Viruses, 12.","DOI":"10.3390\/v12080795"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sachs, L. (1972). Statistische Auswertungsmethoden, Springer.","DOI":"10.1007\/978-3-662-10037-0"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1099\/jgv.0.000422","article-title":"New effective chemically synthesized anti-smallpox compound NIOCH-14","volume":"97","author":"Mazurkov","year":"2016","journal-title":"J. Gen. Virol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/3\/377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:38:46Z","timestamp":1760161126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/3\/377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["pathogens10030377"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10030377","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]}}}